Feicheng Market Supervision Bureau Conducts Special Inspection on Medical Device Safety in Aesthetic Institutions

Deep News
11/11

Recently, the Market Supervision Bureau of Feicheng City, Shandong Province, launched a special inspection campaign targeting the quality and safety of medical devices in aesthetic institutions. The initiative aims to comprehensively identify and mitigate risks, ensuring standardized industry development.

The inspection focused on key public concerns, particularly widely used aesthetic consumables such as hyaluronic acid injections, as well as critical equipment like radiofrequency (skin) therapy devices and intense pulsed light (IPL) beauty machines. Authorities scrutinized six critical aspects: institutional licensing compliance, procurement channel legitimacy, product registration status, verification of incoming goods, storage conditions, and disposal of expired devices. The campaign also intensified crackdowns on illegal practices, including the use of unlicensed or expired medical devices, to ensure effective oversight.

To date, the inspection has covered five aesthetic institutions. Three were found to have issues such as irregular procurement records, substandard storage conditions, and incomplete equipment maintenance logs. These institutions have been ordered to rectify the problems within a stipulated timeframe, reinforcing their primary responsibility and improving lifecycle management of medical devices.

Moving forward, the Feicheng Market Supervision Bureau will enhance its three-tier coordination mechanism involving municipal, district, and local offices. It will also strengthen cross-department collaboration and long-term regulatory frameworks to promote industry self-discipline. Follow-up inspections will be conducted to monitor rectification progress, ensuring a safer and more reliable medical aesthetic market for consumers.

免責聲明:投資有風險,本文並非投資建議,以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請,作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考,不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證,投資者應自行研究並在投資前尋求專業建議。

熱議股票

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10